Vascodagama Online Journal

Antibody-mediated Rejection Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players – Bristol-Myers Squibb, CSL Behring, Hansa Biopharma, Sanofi, Talaris, Viela Bio

 Breaking News
  • No posts were found

Antibody-mediated Rejection Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players – Bristol-Myers Squibb, CSL Behring, Hansa Biopharma, Sanofi, Talaris, Viela Bio

November 30
03:57 2022
Antibody-mediated Rejection Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players -  Bristol-Myers Squibb, CSL Behring, Hansa Biopharma, Sanofi, Talaris, Viela Bio
DelveInsight Business Research LLP
As per DelveInsight, the Antibody-mediated Rejection Therapeutics Market dynamics are set to evolve in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.

DelveInsight’s “Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Antibody-mediated Rejection market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Antibody-mediated Rejection market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Antibody-mediated Rejection Market

Antibody-mediated Rejection: An Overview

Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably leads to allograft loss. AMR poses a significant and continued challenge for long-term graft survival in kidney transplantation. In the continuum of allograft rejection, the development of antibodies plays a critical role, and antibodies are considered a major cause of allograft failure.

Allograft rejection is a complex process that involves the interplay of different cellular and molecular pathways that cause a broad range of allograft injuries (acute tubular injury, glomerulitis, capillaritis, and fibrinoid necrosis).

Treatment of AMR is often initiated in situations of diffuse C4d positivity with allograft dysfunction, even in the absence of DSA or histological evidence of AMR. In these cases, the inability to measure DSAs may be related to the presence of non-anti-HLA antibodies, to antigens not present on the single-bead assays, or to the possibility that the DSAs may be completely absorbed into the allograft.

Antibody-mediated Rejection Market Key Facts

  • In the year 2021, the total cases of Antibody-Mediated Rejection were 5,100+ in the 7MM, which are expected to grow during the study period, i.e., 2019–2032.

  • As per DelveInsight’s estimates, the total incidence of kidney transplants in the United States was found to be 26,900+ in 2021.

  • As per the study conducted by Calp-Inal et al. (2016), acute and chronic AMR incidence was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR.

  • In 2021, the total Antibody-mediated Rejection (AMR) market size was USD 88.32 million, which is expected to rise by 2032.

  • The total market size of Antibody-Mediated Rejection in the United States accounted for USD 65.58 million in 2021.

  • In EU5, the total market size of Antibody-Mediated Rejection was USD 20.50 million in 2021.

  • Some of the major emerging therapies in the late phase of clinical development in the Antibody-mediated Rejection (AMR) therapeutics market include CSL Behring (Clazakizumab), Hansa Biopharma (Imlifidase), Sanofi (BIVV020), and Viela Bio (VIB4920).

Antibody-mediated Rejection Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Antibody-mediated Rejection market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Antibody-mediated Rejection market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Antibody-mediated Rejection Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers the Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Antibody-mediated Rejection Market Will Evolve by 2032 @

Antibody-Mediated Rejection Therapeutics Market 

The primary aim of therapeutic approaches to Antibody-mediated rejection is to remove circulating donor-specific anti-HLA antibodies and to block their effects, reduce their production, or both. To improve the treatment scenario, globally, several key companies are actively working in the Antibody-Mediated Rejection Therapeutics Market. 

Some of the key players in the Antibody-Mediated Rejection market include:

  • Bristol-Myers Squibb

  • CSL Behring

  • Hansa Biopharma AB

  • Sanofi

  • Talaris Therapeutics

  • Horizon Therapeutics

  • Viela Bio 

And others.

Antibody-Mediated Rejection Therapies covered in the report includes:

  • Nulojix (belatacept)

  • Clazakizumab

  • Imlifidase

  • BIVV020

  • VIB4920

And many others.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Antibody-mediated Rejection Competitive Intelligence Analysis

4. Antibody-mediated Rejection Market Overview at a Glance

5. Antibody-mediated Rejection Disease Background and Overview

6. Antibody-mediated Rejection Patient Journey

7. Antibody-mediated Rejection Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Antibody-mediated Rejection Treatment Algorithm, Current Treatment, and Medical Practices

9. Antibody-mediated Rejection Unmet Needs

10. Key Endpoints of Antibody-mediated Rejection Treatment

11. Antibody-mediated Rejection Marketed Products

12. Antibody-mediated Rejection Emerging Drugs and Latest Therapeutic Advances

13. Antibody-mediated Rejection Seven Major Market Analysis

14. Attribute Analysis

15. Antibody-mediated Rejection Market Outlook (In US, EU5, and Japan)

16. Antibody-mediated Rejection Access and Reimbursement Overview

17. KOL Views on the Antibody-mediated Rejection Market

18. Antibody-mediated Rejection Market Drivers

19. Antibody-mediated Rejection Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Antibody-Mediated Graft Rejection Therapeutics Pipeline Assessment

“Antibody-Mediated Graft Rejection Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Antibody-Mediated Graft Rejection market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States